MedinCell启动其Covid-19预防计划的首个临床试验
泛欧证券交易所：MEDCL•法国蒙彼利埃•2020年9月29日– CEST下午6:30
第一位病人
该药物于今日给药。该试验旨在验证依维菌素口服形式连续给药的安全性。
同时，
基于MedinCell的BEPO®技术的几种长效注射剂
正在体内进行测试1个月的积极可注射预防性治疗应准备在年底前进入法规制定
MedinCell可能最早在2021年就申请市场许可。
这种预防性治疗在所有情况下都必不可少预防策略
https://www.medincell.com/wp-content/uploads/2020/09/EN-PR-ivermectine_290920.pdf
France-based MedinCell Initiates Ivermectin Clinical Trial Targeting COVID-19 with Prophylactic Strategy
MedinCell
treated the first patient in a clinical trial aimed at validating the safety of continuous administration of Ivermectin in an oral form.Several long-acting injectable formulations based on MedinCell’s BEPO® technology
are simultaneously being tested in vivo.The France-based company plans for a 1-month active injectable prophylactic treatment,